NEOGENOMICS INC

NeoGenomics, Inc., a Nevada corporation (referred to individually as the Company or collectively with its subsidiaries as NeoGenomics, we, us, or our in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC ( Nasdaq ) under the symbol NEO. Overview NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a network of cancer-focused testing laboratories in the United States and the United Kingdom. Our mission is to save lives by improving patient care. Our vision is to become the world’s leader in cancer testing, information, and decision support by providing uncompromising quality, exceptional service, and innovative solutions. As of December 31, 2025, the Company operated College of American Pathologists ( CAP ) accredited and Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Durham, North Carolina; Ramsey, New Jersey; and Houston, Texas; and an International Organization for Standardization ( ISO ) certified, CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. We also have several, small, non-processing laboratory locations across the United States for providing analysis services.